Hanna Grindebacke

Appearances

EFFICACY AND SAFETY OF BENRALIZUMAB IN ADULTS AND ADOLESCENTS WITH EOSINOPHILIC ESOPHAGITIS: RESULTS FROM THE 24-WEEK DOUBLE-BLIND PERIOD OF THE PHASE 3 MESSINA TRIAL
Date
May 8, 2023
BACKGROUND: Tools predicting incident esophageal adenocarcinoma (EAC) and gastric cardia adenocarcinoma (GCA) that can be automated in electronic health records (EHRs) to guide screening decisions are needed…
Speakers
Marc Rothenberg
Margaret Collins
Albert Bredenoord
Ikuo Hirano
Kathryn Peterson
University of Utah
Laura Brooks
Harald Fjallbrant
Hanna Grindebacke
Calvin Ho
Matthew Keith
Christopher McCrae
Wendy White
Catherine Datto
Presenter
Evan Dellon
University of North Carolina School of Medicine